Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Effect of pH on colloidal structures in human intestinal fluids and intestinal absorption of anticancer drugs

Obiettivo

Oral administration followed by intestinal absorption is the preferred way to deliver drugs to the body. Therefore, estimating the
correct oral dose to achieve a therapeutic effect is an important challenge when developing drug products. Predicting intestinal drug
absorption needs to consider multiple influencing factors, including properties of the drug, the formulation, and the human intestinal
fluids (HIF). One of the critical factors of HIF is pH, as it may influence intestinal drug absorption both directly and indirectly. The direct
effect of pH on a drugs ionisation state and, subsequently, intestinal absorption is widely known. However, the effect of pH on the
solubilisation and absorption of lipophilic drugs by changing the colloidal structures present in HIF, has not yet been systematically
analysed.

Understanding this indirect pH effect is especially needed to improve dose predictions for drugs with a narrow therapeutic window
such as anticancer drugs, and address both inefficiency and potential side effects. The proposed project therefore aims to understand
and predict the pH effect on colloidal structures in HIF and how it affects the absorption potential of anticancer drugs in both fasted
and fed state conditions.

To achieve its goal, the project combines the expertise of the host group at KU Leuven in absorption profiling using in vitro and in
vivo methods with the applicants experience in predictive in silico modelling. This approach will provide unique insights into the
indirect pH effect on drug absorption and contribute to the development of in silico predictive models to guide the early-stage
formulation and dose optimisation of anticancer drugs. As such, the project will have important value for pipelining new anticancer
drugs and will benefit the European Commission priorities for 2019-2024, such as the pharmaceutical strategy and Europes Beating
Cancer Plan.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-MSCA-2022-PF-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

KATHOLIEKE UNIVERSITEIT LEUVEN
Contributo netto dell'UE
€ 175 920,00
Indirizzo
OUDE MARKT 13
3000 Leuven
Belgio
Regione
Vlaams Gewest Prov. Vlaams-Brabant Arr. Leuven
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
Nessun dato

Partner (1)